These authors contributed equally to this work. Keywords: ATG13, ATG101, autophagy, RB1CC1, ULK1Abbreviations: ACTB/b-actin, actin, b; AMPK, AMP-activated protein kinase; ATG, autophagy-related; Baf A1, bafilomycin A 1 ; BECN1, Beclin 1, autophagy-related; EBSS, Earle's balanced salt solution; GFP, green fluorescent protein; GST, glutathione S-transferase; KO, knockout; LIR, LC3-interacting region; MAP1LC3/LC3, microtubule-associated protein 1 light chain 3; MEF, mouse embryonic fibroblast; MIM, MIT-interacting motif; MIT, microtubule interacting and transport; (M)TOR, (mechanistic) target of rapamycin (serine/threonine kinase); PAS, phagophore assembly site; PtdIns3K, phosphatidylinositol 3-kinase; RB1CC1/FIP200, RB1-inducible coiled-coil 1; SQSTM1/p62, sequestosome 1; ULK1/2, unc-51 like autophagy activating kinase 1/2.Autophagy describes an intracellular process responsible for the lysosome-dependent degradation of cytosolic components. The ULK1/2 complex comprising the kinase ULK1/2 and the accessory proteins ATG13, RB1CC1, and ATG101 has been identified as a central player in the autophagy network, and it represents the main entry point for autophagy-regulating kinases such as MTOR and AMPK. It is generally accepted that the ULK1 complex is constitutively assembled independent of nutrient supply. Here we report the characterization of the ATG13 region required for the binding of ULK1/2. This binding site is established by an extremely short peptide motif at the C terminus of ATG13. This motif is mandatory for the recruitment of ULK1 into the autophagy-initiating high-molecular mass complex. Expression of a ULK1/2 binding-deficient ATG13 variant in ATG13-deficient cells resulted in diminished but not completely abolished autophagic activity. Collectively, we propose that autophagy can be executed by mechanisms that are dependent or independent of the ULK1/2-ATG13 interaction.

Highlights d Autophagy and the autophagy-inducing kinase ULK1 affect TNF-induced cell death d Ablation of ULK1 expression or activity enhances complex IIb/necrosome formation d The necroptosis-regulating kinase RIPK1 is a substrate of ULK1 d ULK1-dependent phosphorylation of RIPK1 at Ser357 reduces TNF-induced cell death

The biogenesis of small uridine-rich nuclear ribonucleoproteins (UsnRNPs) depends on the methylation of Sm proteins catalyzed by the methylosome and the subsequent action of the SMN complex, which assembles the heptameric Sm protein ring onto small nuclear RNAs (snRNAs). In this sophisticated process, the methylosome subunit pICln (chloride conductance regulatory protein) is attributed to an exceptional key position as an ‘assembly chaperone’ by building up a stable precursor Sm protein ring structure. Here, we show that—apart from its autophagic role—the Ser/Thr kinase ULK1 (Uncoordinated [unc-51] Like Kinase 1) functions as a novel key regulator in UsnRNP biogenesis by phosphorylation of the C-terminus of pICln. As a consequence, phosphorylated pICln is no longer capable to hold up the precursor Sm ring structure. Consequently, inhibition of ULK1 results in a reduction of efficient UsnRNP core assembly. Thus ULK1, depending on its complex formation, exerts different functions in autophagy or snRNP biosynthesis.

No abstract

Protein-arginine methylation is a common posttranslational modification, crucial to various cellular processes, such as protein-protein interactions or binding to nucleic acids. The central enzyme of symmetric protein arginine methylation in mammals is the protein arginine methyltransferase 5 (PRMT5). While the methylation reaction itself is well understood, recruitment and differentiation among substrates remain less clear. One mechanism to regulate the diversity of PRMT5 substrate recognition is the mutual binding to the adaptor proteins pICln or RioK1. Here, we describe the specific interaction of Nuclear Factor 90 (NF90) with the PRMT5-WD45-RioK1 complex. We show for the first time that NF90 is symmetrically dimethylated by PRMT5 within the RG-rich region in its C-terminus. Since upregulation of PRMT5 is a hallmark of many cancer cells, the characterization of its dimethylation and modulation by specific commercial inhibitors in vivo presented here may contribute to a better understanding of PRMT5 function and its role in cancer.